US Stock MarketDetailed Quotes
CALT Calliditas Therapeutics
- 38.190
- +0.040+0.10%
Close Jul 26 16:00 ET
- 37.000
- -1.190-3.12%
Post 20:01 ET
1.02BMarket Cap-21134P/E (TTM)
38.190High37.810Low3.64KVolume38.140Open38.150Pre Close138.10KTurnover0.02%Turnover RatioLossP/E (Static)26.84MShares41.90052wk High92.47P/B611.86MFloat Cap15.25052wk Low--Dividend TTM16.02MShs Float41.900Historical High--Div YieldTTM1.00%Amplitude10.820Historical Low37.959Avg Price1Lot Size
Calliditas Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 14.54%-198.21M | -39.60%-434.66M | -90.07%22.84M | 49.87%-62.53M | 27.62%-163.03M | -21.17%-231.94M | 32.55%-311.35M | 242.65%230.03M | -275.18%-124.73M | -69.46%-225.23M |
| Net income from continuing operations | -13.19%-203.83M | 11.59%-373.06M | 28.52%41.76M | -340.48%-159.57M | 64.18%-75.17M | 13.58%-180.07M | 19.55%-421.94M | 114.63%32.5M | -561.14%-36.23M | -31.65%-209.84M |
| Depreciation and amortization | ---- | 277.34%48.73M | ---- | ---- | ---- | ---- | -62.50%12.91M | ---- | ---- | ---- |
| Other non cash items | -40.09%16.26M | -224.04%-19.73M | -579.56%-98.15M | 424.01%58.55M | -151.51%-7.27M | 435.64%27.14M | 259.12%15.9M | 26.72%-14.44M | 25.38%11.17M | 38.03%14.1M |
| Change In working capital | 121.90%13.62M | -190.18%-79.74M | -115.86%-28.12M | 170.74%60.16M | -134.58%-49.56M | -459.95%-62.22M | 1,516.45%88.42M | 592.35%177.32M | -72.84%-85.05M | -222.01%-21.13M |
| -Change in receivables | ---- | -98.73%-182.59M | ---- | ---- | ---- | ---- | -684.48%-91.88M | ---- | ---- | ---- |
| -Change in inventory | ---- | -508.45%-16.78M | ---- | ---- | ---- | ---- | -190.62%-2.76M | ---- | ---- | ---- |
| -Change in other current liabilities | ---- | -34.65%119.63M | ---- | ---- | ---- | ---- | 909.63%183.06M | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 14.54%-198.21M | -39.60%-434.66M | -90.07%22.85M | 49.87%-62.53M | 27.62%-163.03M | -21.17%-231.94M | 32.55%-311.35M | 242.65%230.03M | -275.17%-124.73M | -69.46%-225.23M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -167.17%-13.75M | -60.53%-2.36M | -735.25%-7.42M | 78.86%-5.15M | 72.51%-1.47M | -276.27%-888K | ||||
| Net PPE purchase and sale | ---- | -409.08%-12.79M | ---- | ---- | ---- | ---- | 61.87%-2.51M | ---- | ---- | ---- |
| Net intangibles purchase and sale | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| Net investment purchase and sale | ---- | 63.62%-958K | ---- | ---- | ---- | ---- | -56.17%-2.63M | ---- | ---- | ---- |
| Net other investing changes | ---- | 0.00%1K | 209.65%11.39M | -735.25%-7.42M | ---- | ---- | --1K | --3.68M | -276.27%-888K | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -32.44%-3.86M | -167.20%-13.75M | -60.57%-2.35M | -735.25%-7.42M | -662.59%-1.06M | -9.88%-2.91M | 78.87%-5.14M | 72.53%-1.47M | -276.27%-888K | 99.25%-139K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -84.14%-5.47M | -65.34%199.65M | -26.22%208.52M | -12.42%-2.89M | -101.28%-3.02M | -104.94%-2.97M | 32.36%575.99M | 784.51%282.64M | -100.53%-2.57M | 32,996.37%235.87M |
| Net issuance payments of debt | -84.14%-5.47M | -53.07%226.28M | -6.84%235.15M | -12.42%-2.89M | -101.29%-3.02M | -79.07%-2.97M | 148.59%482.13M | 11,219.91%252.42M | -101.30%-2.57M | 66,748.15%233.94M |
| Net common stock issuance | ---- | --0 | --0 | --0 | --0 | ---- | --0 | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | ---- | --0 | --0 | --0 | --0 | ---- | --95.12M | --31.48M | --0 | --1.93M |
| Net other financing activities | ---- | -2,011.50%-26.63M | ---- | ---- | ---- | ---- | 98.48%-1.26M | 96.77%-1.26M | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -84.14%-5.47M | -65.34%199.65M | -26.22%208.52M | -12.42%-2.89M | -101.28%-3.02M | -104.94%-2.97M | 32.36%575.99M | 784.53%282.64M | -100.53%-2.57M | 32,996.37%235.87M |
| Net cash flow | ||||||||||
| Beginning cash position | -22.04%973.73M | 30.73%1.25B | 6.89%786.88M | 2.29%866.18M | 22.80%1.01B | 30.73%1.25B | -4.09%955.51M | -36.75%736.16M | 19.38%846.8M | -4.84%825.41M |
| Current changes in cash | 12.74%-207.53M | -195.86%-248.75M | -55.20%229.01M | 43.18%-72.83M | -1,692.40%-167.11M | -77.45%-237.82M | 611.16%259.49M | 345.91%511.2M | -128.28%-128.18M | 106.90%10.49M |
| Effect of exchange rate changes | 1,795.75%44.11M | -178.05%-26.61M | -2,534.30%-42.16M | -136.84%-6.46M | 80.66%19.69M | -40.65%2.33M | 242.00%34.09M | 501.86%1.73M | 1,364.44%17.54M | 286.43%10.9M |
| End cash Position | -20.06%810.32M | -22.04%973.73M | -22.04%973.73M | 6.89%786.88M | 2.29%866.18M | 22.80%1.01B | 30.73%1.25B | 30.73%1.25B | -36.75%736.16M | 19.38%846.8M |
| Free cash flow | 14.54%-198.21M | -42.56%-447.44M | -95.58%10.06M | 49.87%-62.53M | 27.62%-163.03M | -21.17%-231.94M | 35.18%-313.87M | 223.71%227.52M | -275.17%-124.73M | -69.46%-225.23M |
| Currency Unit | SEK | SEK | SEK | SEK | SEK | SEK | SEK | SEK | SEK | SEK |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg